2025年以来，公募基金行业前8个月基金经理离任变更达242人次，这一数据创下近年新高。在看似频繁的人才变更流动背后，折射出了公募行业的人才建设 新变化。公募基金在平台化的投研体系建设下，不固步自封，不机械组合，更注重人才体系的可持续与价值创造。 比如，包括嘉实基金在内的很多头部基金公司，主动对部分双基金经理共管的产品进行了变革调整——资深的基金经理卸任共管产品，已有业绩沉淀的"中 生代"独挑大梁。 这是"传帮带"中很常见的一环，也是公募基金常见的人才培养方式，共同管理的经历，让团队的经验、投研的文化得以传承。卸任共管产品后，老将、新将 在专注各自的产品同时，共享平台研究资源、传承同一团队方法框架。 基金经理的接力，并非简单的交接，而是嘉实投研文化、方法论与投研纪律的传承与迭代。以其在科技领域的投资研究力量为例，嘉实最早一批扎根科技行 业研究与投资的张丹华等人，以第一性原理聚焦科技的底层规律；嘉实大科技研究总监王贵重、嘉实港股互联网基金经理王鑫晨等将投资视野既扎根TMT 领域，又前瞻性地拓展至人工智能、生物科技等交叉学科和全球不同市场；同时嘉实创新先锋基金经理彭民、嘉实前沿创新基金经理何鸣晓等持续跟踪科技 最 ...

Core Insights - As of August 29, 2023, 969 out of 976 comparable ordinary equity funds have reported positive performance in the first eight months of the year, representing a remarkable 99% success rate, with only 7 funds showing declines [1][3]. Fund Performance - The top-performing fund, Huaan Medical Biotechnology Stock A/C, achieved a staggering increase of 107.64% and 107.03%, respectively, making it the only fund to double its value [1][4]. - Other notable funds with over 90% growth include Jiashi Mutual Fund's Jiashi Huirong Selected Stock A/C and Fuguo Medical Innovation Stock A/C, with increases ranging from 91.34% to 98.55% [1][2][5]. Fund Management - The fund managers of the top-performing funds are seasoned professionals with extensive backgrounds in the medical and pharmaceutical sectors. For instance, Jiashi Huirong's manager, Hao Miao, has over 6 years of experience, while Fuguo Medical Innovation's managers, Zhao Wei and Wang Chao, have nearly 8 years of combined experience [2][3]. - Huaan Medical Biotechnology is managed by Sang Xiangyu, who has been with Huaan Fund since 2018 and has a background in investment research [1][2]. Market Trends - The strong performance of A-share markets has contributed to the overall success of equity funds, with only 7 funds reporting declines, the most significant being Minsheng Jianyin's decline of 9.51% [3][4]. - The underperformance of certain funds, such as Qianhai Kaiyuan Traditional Chinese Medicine Stock A/C, which fell by 1.25% and 1.09%, indicates a potential shift in market preferences away from traditional medicine towards innovative pharmaceutical sectors [3][4].

Group 1 - In the first half of 2025, 822 out of 993 comparable ordinary stock funds achieved positive performance, representing 83% of the total [1] - The top three performing funds saw gains exceeding 60%, with 华安医药生物股票发起式A at 66.44%, 华安医药生物股票发起式C at 66.07%, and 嘉实互融精选股票A at 60.26% [1][2] - 华安医药生物股票发起式 has a cumulative return of over 68% since its inception, heavily investing in pharmaceutical companies such as 三生制药 and 信达生物 [1] Group 2 - 嘉实互融精选股票 also focuses on pharmaceutical stocks, with top holdings including 康方生物 and 百济神州, and has shown significant growth exceeding 55% in the first half of 2025 [2] - Several other pharmaceutical-themed funds, including 平安医药精选股票 and 富国医药创新股票, also reported gains over 55% [2] - Conversely, 11 ordinary stock funds experienced declines exceeding 10%, with 长信消费精选量化股票C and A dropping 12.38% and 12.20% respectively, primarily due to their focus on the consumer sector [2][3] Group 3 - The 长信消费精选量化股票 fund, which is heavily invested in the liquor sector, has seen a cumulative decline of 50% since its establishment [3] - 北信瑞丰优选成长 fund, managed by a relatively inexperienced manager, has not included any pharmaceutical stocks in its top holdings since 2022, focusing instead on liquor stocks [3] - Other funds with significant declines include 民生加银优选股票, which fell by 10.64%, and 广发高端制造股票C and A, which dropped by 10.57% and 10.39% respectively [4]

Core Viewpoint - The A-share market has shown strong performance in the first half of 2025, with the Shanghai Composite Index stabilizing above 3400 points and reaching a new high for the year [1] Group 1: Investment Strategies for the Second Half - Investors often mistakenly believe that strong-performing funds from the first half will continue to perform well in the second half, which is a significant misconception in fund investment [3] - The best-performing funds in the first half of 2023 were those focused on the Hong Kong innovative pharmaceutical sector, with several ETFs and equity funds achieving over 50% gains [4] - Historical data indicates that funds that performed well in the first half often see a decline in performance by the end of the year, as seen with AI and gaming-focused funds in 2023 [4][5] Group 2: Focus Areas for Investment - The technology growth sector is expected to become a key market focus again in the second half, driven by strong performances in the U.S. stock market, particularly in AI-related companies [6] - The robotics sector remains a promising area for investment, with several funds achieving over 40% gains despite previous adjustments due to valuation concerns [7] - Dividend funds are gaining popularity due to their stable cash flow and bond-like characteristics, with many achieving positive returns in 2023 [10] Group 3: REITs Market Expansion - The REITs market has been expanding, with a total of 73 products now available, focusing on emerging sectors like new infrastructure and smart cities [12] - REITs have shown strong performance in 2023, with specific products like the Jia Shi Wu Mei Consumption REIT and Hua Xia Da Yue Cheng Commercial REIT achieving over 50% and 49.58% gains, respectively [12]